Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations.
He Q, Liu J, Cai X, He M, Li C, Liang H, Cheng B, Xia X, Guo M, Liang P, Zhong R, Li F, Yu Z, Zhao Y, Ou L, Xiong S, Li J, Zhang J, He J, Liang W.
He Q, et al. Among authors: cai x.
Transl Lung Cancer Res. 2021 Nov;10(11):4120-4129. doi: 10.21037/tlcr-21-649.
Transl Lung Cancer Res. 2021.
PMID: 35004243
Free PMC article.